Health & Safety Industry Today
Global Pancreatic Cancer Precision Medicine Market to Reach US$2.47 Billion by 2033 Amid Advances in Targeted Therapies
Pancreatic Cancer Precision Medicine Market Analysis
The global Pancreatic Cancer Precision Medicine Market is projected to grow from US$ 610 million in 2024 to approximately US$ 2,467.83 million by 2033, registering a CAGR of 16.8% during the forecast period from 2025 to 2033. Market growth is being driven by the increasing adoption of targeted therapies, immunotherapies, and advanced diagnostic technologies such as liquid biopsies and genomic profiling. Rising awareness regarding personalized oncology and continuous advancements in molecular diagnostics are further supporting market expansion across major healthcare regions.
Global Pancreatic Cancer Precision Medicine Industry Overview
The global pancreatic cancer precision medicine industry is witnessing strong growth due to the rising focus on individualized cancer treatment and advancements in precision oncology technologies. Targeted therapies and precision immunotherapies are increasingly being used to improve therapeutic effectiveness while reducing toxicity associated with conventional chemotherapy. In addition, innovations in diagnostic technologies, including genetic sequencing, biomarker testing, and liquid biopsy solutions, are improving early disease detection and treatment selection. These developments are helping clinicians design customized therapies based on each patient’s molecular and genetic profile.
The integration of next-generation sequencing and bioinformatics is significantly enhancing the identification of novel therapeutic targets and accelerating drug discovery efforts for pancreatic cancer treatment. Pharmaceutical companies, research institutes, and government organizations are investing heavily in precision oncology research to develop more effective therapies for this highly aggressive cancer type. Research funding initiatives and collaborative programs are also contributing to rapid innovation within the industry. Furthermore, the increasing incidence of pancreatic cancer, supported by aging demographics and changing lifestyle patterns, is creating substantial demand for advanced treatment options. Growing collaboration between biotechnology firms, healthcare providers, and academic institutions is expanding the availability of innovative therapies and supporting long-term market growth.
Request Sample Report:
Top Companies in the Pancreatic Cancer Precision Medicine Pipeline
Revolution Medicines
Revolution Medicines is one of the leading companies in pancreatic cancer precision medicine in 2026. Its lead candidate, daraxonrasib (RMC-6236), is a pan-RAS inhibitor currently in Phase III clinical trials for metastatic pancreatic ductal adenocarcinoma (PDAC). Clinical results demonstrated substantial survival improvement in KRAS-driven pancreatic cancer patients, positioning the company at the forefront of KRAS-targeted oncology innovation.
Astellas Pharma is advancing setidegrasib (ASP3082), the first KRAS G12D-targeted protein degrader to enter Phase III development for pancreatic cancer. The company is focusing heavily on targeted protein degradation technologies for precision oncology applications in KRAS-mutated tumors.
Bristol Myers Squibb is actively developing KRAS G12D-directed precision therapies, including MRTX1133 combination programs. The company is exploring synthetic lethality strategies and combination approaches involving PARP inhibitors and immunotherapy in pancreatic cancer treatment.
Marker Therapeutics is focused on personalized T-cell immunotherapies for pancreatic cancer. Its MultiTAA T-cell therapy platform targets multiple tumor-associated antigens to improve immune response in difficult-to-treat pancreatic tumors.
Oncotelic Therapeutics is developing Trabedersen, a TGF-β2 antisense immunotherapy designed to modify the pancreatic tumor microenvironment and strengthen anti-cancer immune activity. The therapy remains among the advanced precision immunotherapy programs in the pipeline.
Chia Tai Tianqing Pharmaceutical Group
Chia Tai Tianqing Pharmaceutical Group is progressing TQB2868, a bispecific immunotherapy candidate in advanced clinical development. The company is increasingly recognized for expanding precision oncology research focused on pancreatic cancer immunotherapy.
Incyte Corporation is developing INCB161734, an oral KRAS G12D inhibitor targeting metastatic pancreatic cancer. The company is strengthening its oncology portfolio through next-generation targeted therapies and mutation-specific drug development programs.
Arvinas is utilizing PROTAC-based targeted protein degradation technology to develop ARV-806, a KRAS-targeted degrader for pancreatic and other KRAS-driven cancers. The company is emerging as an important innovator in precision oncology degradation platforms.
Kestrel Therapeutics entered clinical development with KST-6051, a pan-KRAS inhibitor targeting multiple KRAS mutations associated with pancreatic cancer. The company is focusing on overcoming resistance mechanisms across RAS-driven malignancies.
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics is advancing BBO-11818, a pan-KRAS inhibitor that received regulatory attention for KRAS-mutated pancreatic cancer. The company is investing heavily in genetically guided oncology therapies and precision medicine development.
Companies Launch in the Pancreatic Cancer Precision Medicine Market
· Revolution Medicines launched major clinical expansion activities for daraxonrasib (RMC-6236) in 2026, including initiation of the global Phase III RASolute 303 trial for metastatic pancreatic cancer. The company also received FDA authorization for expanded patient access to the therapy following strong survival data in KRAS-driven pancreatic cancer.
· Astellas Pharma advanced the launch of its KRAS G12D-targeted degrader setidegrasib (ASP3082) into Phase III clinical development in 2026, becoming one of the first companies to commercialize targeted protein degradation strategies for pancreatic cancer precision medicine.
· Caris Life Sciences introduced the Caris AI Insights pancreatic cancer signature platform in 2026 to improve first-line therapy selection and treatment de-escalation decisions using AI-driven molecular profiling and genomic analytics.
· Genialis commercially launched its krasID biomarker platform between 2024 and 2025 to predict patient response to KRAS inhibitors in pancreatic cancer. The company also partnered with PanCAN to validate precision diagnostic applications for KRAS-targeted therapies.
· Merus N.V. achieved a major milestone in 2024 with FDA approval of Bizengri for NRG1 fusion-positive pancreatic cancer, representing one of the first precision-targeted therapies approved for this molecular subtype.
· Frontier Medicines expanded development of FMC-376, a dual ON/OFF KRAS G12C inhibitor platform presented during AACR 2024. The company highlighted combination precision immunotherapy strategies for KRAS-mutated pancreatic tumors.
· Incyte Corporation accelerated development of KRAS G12D-targeted precision oncology programs for pancreatic cancer during 2025–2026, positioning itself among the emerging leaders in mutation-specific targeted therapies. Community discussions and ongoing trial enrollment significantly increased visibility for the company’s pancreatic cancer pipeline.
· BridgeBio Oncology Therapeutics strengthened its pancreatic cancer precision oncology portfolio during 2025–2026 through development of pan-KRAS targeted therapies aimed at overcoming resistance mechanisms in KRAS-mutant tumors.
· Propanc Biopharma expanded visibility of its PRP proenzyme therapy platform in 2026, reporting strong preclinical pancreatic tumor inhibition results and positioning the therapy as a next-generation precision oncology candidate.
· Kumquat Biosciences entered a major oncology collaboration with Bayer in 2025 to advance KRAS G12D-targeted precision therapies for pancreatic cancer and other KRAS-driven solid tumors, significantly expanding commercialization potential.
Growth Driving the Pancreatic Cancer Precision Medicine Market
Advancements in Targeted Therapies and Immunotherapies
Targeted therapies and immunotherapies are transforming pancreatic cancer treatment by offering more personalized and effective therapeutic approaches with reduced side effects. These advanced treatments focus on specific genetic mutations and molecular markers present in cancer cells, enabling precise targeting while minimizing damage to healthy tissues. Targeted therapies help inhibit tumor growth and progression, whereas immunotherapies enhance the immune system’s ability to detect and destroy cancer cells. Such innovations are particularly valuable for pancreatic cancer, which is often diagnosed at an advanced stage and responds poorly to traditional treatment methods. Increasing clinical success rates and broader accessibility of these therapies are encouraging greater adoption among healthcare providers and patients. As a result, the growing development and use of precision-based therapies are becoming major factors supporting the expansion of the pancreatic cancer precision medicine market.
Increased Research and Development Investments
Growing investments in research and development from pharmaceutical companies, biotechnology firms, government agencies, and academic institutions are significantly accelerating the advancement of the pancreatic cancer precision medicine market. These investments are supporting the discovery, development, and clinical evaluation of innovative targeted therapies, immunotherapies, and companion diagnostic technologies. Strategic collaborations between industry participants and research organizations are enhancing scientific innovation by combining technological expertise and financial resources to speed up treatment development. Government-funded cancer research programs and grants are also contributing to a deeper understanding of pancreatic cancer biology, genetics, and treatment resistance mechanisms. Such funding plays a crucial role in overcoming the complexity of the disease and improving therapeutic effectiveness. With increasing R&D activities worldwide, more personalized treatment solutions are entering the market, improving patient outcomes and driving sustained growth in the precision medicine industry.
Integration of Next-Generation Sequencing and Bioinformatics
The integration of next-generation sequencing (NGS) and bioinformatics technologies is playing a vital role in advancing precision medicine for pancreatic cancer. These technologies enable researchers and clinicians to identify genetic mutations, biomarkers, and potential therapeutic targets with greater accuracy and speed. NGS allows comprehensive analysis of tumor genetics, helping physicians develop personalized treatment plans based on the molecular characteristics of each patient’s cancer. It also assists in detecting tumor heterogeneity and identifying drug resistance patterns, improving treatment selection and monitoring. Bioinformatics tools further support the interpretation of complex genomic data and facilitate its integration into clinical decision-making processes. As these technologies become more affordable and widely accessible, they are enhancing the efficiency of drug discovery and accelerating the development of targeted therapies. This growing adoption of genomic technologies is significantly contributing to the expansion of the pancreatic cancer precision medicine market.
Segment Analysis
Pancreatic Cancer Precision Targeted Therapy Market
The Pancreatic Cancer Precision Targeted Therapy Market is expanding due to increasing demand for personalized treatment approaches that improve survival outcomes in pancreatic cancer patients. Traditional chemotherapy has shown limited effectiveness in advanced pancreatic cancer, encouraging pharmaceutical companies and healthcare providers to adopt targeted therapies that focus on specific genetic mutations such as KRAS, BRCA1, BRCA2, and HER2. Advances in biomarker identification and molecular profiling are helping clinicians select therapies tailored to individual patient characteristics, reducing unnecessary toxicity and improving treatment efficiency. The market is also benefiting from rising investments in oncology research, strategic collaborations between biotechnology firms, and accelerated drug development programs. Regulatory agencies are supporting innovation through orphan drug designations and fast-track approvals for precision oncology therapies. North America currently dominates the market because of advanced healthcare infrastructure and strong research funding, while Asia-Pacific is emerging rapidly due to growing cancer awareness, expanding diagnostic capabilities, and increasing access to personalized medicine technologies.
Pancreatic Cancer Precision Immunotherapy Market
The Pancreatic Cancer Precision Immunotherapy Market is gaining momentum as researchers develop therapies that stimulate the immune system to recognize and destroy pancreatic tumor cells more effectively. Precision immunotherapy combines biomarker analysis, genomic profiling, and immune checkpoint targeting to deliver individualized treatment strategies. Growing understanding of the tumor microenvironment and immune resistance mechanisms has accelerated the development of therapies such as checkpoint inhibitors, cancer vaccines, adoptive cell therapies, and monoclonal antibodies. Although pancreatic cancer has historically shown limited response to conventional immunotherapy, precision-based approaches are improving patient selection and enhancing therapeutic response rates. Pharmaceutical companies are investing heavily in combination therapies that integrate immunotherapy with chemotherapy, radiation, or targeted treatments to improve efficacy. Increased clinical trial activity and advancements in companion diagnostics are further driving market growth. North America leads due to strong oncology research ecosystems, while Europe and Asia-Pacific are witnessing rapid adoption supported by expanding healthcare investments and personalized cancer treatment initiatives.
Pancreatic Cancer Precision Genomic Testing Market
The Pancreatic Cancer Precision Genomic Testing Market is experiencing substantial growth because genomic testing plays a critical role in identifying actionable mutations and guiding individualized treatment decisions. Genomic technologies such as next-generation sequencing, polymerase chain reaction testing, and companion diagnostics enable clinicians to detect mutations associated with pancreatic cancer progression and treatment resistance. Increasing awareness about the value of early mutation detection and personalized medicine is encouraging hospitals and diagnostic laboratories to adopt comprehensive genomic profiling solutions. Pharmaceutical companies are also relying on genomic data to develop targeted therapies and stratify patients for clinical trials. The market benefits from advancements in bioinformatics, artificial intelligence, and data analytics that improve interpretation of complex genomic information. Government initiatives promoting precision medicine and expanding reimbursement policies are supporting broader adoption of genomic testing services. North America remains the largest market due to strong research infrastructure, while Asia-Pacific is growing rapidly with increasing cancer incidence and improving diagnostic accessibility.
Pancreatic Cancer Precision Liquid Biopsy Market
The Pancreatic Cancer Precision Liquid Biopsy Market is growing rapidly as liquid biopsy technologies offer minimally invasive methods for detecting, monitoring, and managing pancreatic cancer. Unlike traditional tissue biopsies, liquid biopsies analyze circulating tumor DNA, circulating tumor cells, exosomes, and other biomarkers obtained from blood samples, enabling faster and safer diagnostic procedures. These technologies support early cancer detection, treatment monitoring, and identification of therapy resistance, making them highly valuable in precision oncology. Increasing demand for non-invasive cancer diagnostics and real-time disease monitoring is encouraging healthcare providers to integrate liquid biopsy testing into clinical practice. Technological advancements in sequencing platforms and biomarker analysis are improving test sensitivity and accuracy, supporting broader market adoption. Biopharmaceutical companies are using liquid biopsy tools to enhance drug development and personalized treatment planning. North America currently dominates the market because of advanced diagnostic infrastructure and strong research funding, while Asia-Pacific is emerging as a high-growth region due to expanding healthcare modernization and cancer screening initiatives.
Ask Analyst for Customization in Report:
Country Analysis
United States Vegetable Oil Market
The United States vegetable oil market is one of the largest globally, supported by strong demand for soybean, canola, sunflower, and other edible oils. Soybean oil remains the most widely produced and consumed oil in the country, extensively utilized in frying applications, food manufacturing, and packaged food products. Changing consumer preferences toward healthier lifestyles are increasing the popularity of premium oils such as olive and avocado oil. In addition, growing awareness regarding trans fats and demand for non-GMO and clean-label products are reshaping purchasing patterns across the market. The industry also faces challenges including fluctuating raw material prices, supply chain uncertainties, and increasing competition from alternative edible oils. Sustainability concerns and responsible sourcing practices are becoming increasingly important as manufacturers focus on environmentally friendly production methods and product innovation to maintain market competitiveness.
Germany Vegetable Oil Market
Germany’s vegetable oil market is primarily driven by health-conscious consumers who prefer healthier edible oils such as olive, sunflower, and rapeseed (canola) oil. Rising adoption of plant-based diets and increasing demand for sustainable and non-GMO food products are supporting market growth. Consumers are also showing greater interest in premium-quality oils due to growing awareness of the nutritional benefits associated with healthy fats. Germany’s strict food safety, quality, and sustainability regulations play a major role in shaping the market by encouraging ethical sourcing and environmentally responsible production practices. Manufacturers are increasingly focusing on transparency, organic offerings, and sustainable packaging solutions to meet evolving consumer expectations. The expanding demand for healthier cooking ingredients and functional food products continues to strengthen the growth prospects of the vegetable oil industry in Germany.
India Vegetable Oil Market
India represents one of the world’s largest vegetable oil markets, supported by rapid urbanization, population growth, and evolving dietary preferences. Sunflower, palm, and soybean oils dominate the market, with sunflower oil witnessing increasing popularity because of its perceived health benefits. Rising disposable income and changing food consumption habits are further contributing to market expansion. The industry is also experiencing greater consolidation and competitive activity, with major companies investing in refinery expansion, production capacity enhancement, and supply chain development to meet rising domestic demand. Businesses are increasingly focusing on regional expansion strategies and product diversification to cater to varying consumer preferences across the country. However, the Indian vegetable oil market remains influenced by factors such as import dependency, price volatility, trade regulations, and sustainability concerns. Companies are strengthening sourcing strategies and operational efficiency to maintain competitiveness and ensure long-term market growth.
Saudi Arabia Vegetable Oil Market
Saudi Arabia’s vegetable oil market is growing steadily due to increasing consumption of packaged foods, expanding urbanization, and rising demand from the food processing sector. Palm oil, soybean oil, and sunflower oil are among the most commonly consumed edible oils in the country. Growing consumer preference for healthier cooking oils and premium-quality food products is further supporting market growth. Since domestic production remains limited, Saudi Arabia relies heavily on imports to satisfy rising demand for vegetable oils. Government initiatives aimed at improving food security and promoting sustainable agricultural practices are also influencing market dynamics. Additionally, increasing awareness regarding non-GMO products, quality standards, and environmentally responsible sourcing is encouraging manufacturers and suppliers to focus on premium and sustainable oil offerings. The market is expected to continue expanding with changing consumer lifestyles and ongoing investments in the food industry.
Market Segmentations
· Therapeutic Approach
· Targeted Therapy
· Immunotherapy
· Chemotherapy-Precision Combinations
· Other Therapeutic Approaches
Diagnostic Technology
· Genomic Testing
· Molecular Diagnostic
· Liquid Biopsy
· Biomarker-based Companion Diagnostics
· Others
Regional Outlook
North America
· United States
· Canada
Europe
· France
· Germany
· Italy
· Spain
· United Kingdom
· Belgium
· Netherlands
· Turkey
Asia Pacific
· China
· Japan
· India
· Australia
· South Korea
· Thailand
· Malaysia
· Indonesia
· New Zealand
Latin America
· Brazil
· Mexico
· Argentina
Middle East & Africa
· South Africa
· Saudi Arabia
· United Arab Emirates
All the Key players have been covered
· Overview
· Key Persons
· Recent Development & Strategies
· Revenue Analysis
Company Analysis:
· AstraZeneca
· Pfizer Inc.
· Novartis AG
· Amgen Inc.
· F. Hoffmann-La Roche Ltd
· Bayer AG
· Eli Lilly and Company
· Merck & Co., Inc.
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.
Contact Us:
Company Name: Renub Research
Contact Person: Rajat Gupta
Phone No: (D) +91-120-421-9822 (IND)
Website: https://www.renub.com/
Email: rajat@renub.com
Share on Social Media
Contact Information
Anurag Saurabh
Renub Research LLP
P 383 Sector 21
Noida
Uttar Pradesh
201301
9868516005
https://www.renub.com/
Other Industry News
Ready to start publishing
Sign Up today!
